Identifying links between specific infectious agents and cancer greatly impacts the prevention of these cancers. Furthermore, understanding the role of cellular factors that mediate the effect of infectious agents may reveal additional cancer control strategies. A potential association between cancers and infection with mycoplasma, the smallest self-replicating prokaryote, has been suspected since the 1960's (reviewed in [1]). However, early evidence was weakened by the difficult culture conditions demanded by these fastidious microbes. More recent studies have used techniques such as PCR, immunohistochemistry, and serum antibody status. These improved detection methods have shown that healthy individuals are often colonized without obvious clinical effects [2, 3]. Later studies continue to support an association between various species of mycoplasma and human cancers (e.g., [4-8]).
This study by Barykova et al. [7] is the latest of several that indicate a strong link between mycoplasma species and prostate cancer [8, 9]. Barykova et al. used real time PCR to demonstrate that Mycoplasma hominis levels in biopsies from patients with high-grade prostatic intraepithelial neoplasia (HGPIN) or prostate cancer (PCa) were triple that of patients with benign prostatic hyperplasia (BPH, p = 0.002). Other species commonly found in the urogenital tract, M. genitalium and Ureaplasma urealitycum, were detected at a lower frequency. Most significantly, no mycoplasma species were detected in control samples from lesion free men. Culturing confirmed the presence of M. hominis and U. urealitycum in prostate tissue (M. genitalium was not cultured). Finally, antibodies against M. hominis protein p120 were detected in the serum of HGPIN or PCa patients twice as frequently as in patients with BPH. The Barykova et al. study is corroborated by another study that determined that PCa patients were more likely to bear antibodies against U. urealitycum [8]. Finally, M. genitalium and M. hyorhinis infection caused the malignant transformation of benign human prostate (BPH-1) cells in vitro [9].
Laboratory studies strongly support the ability of mycoplasma to cause or promote oncogenic transformation. Several different species have been proven to transform rodent and human lines of diverse lineages in vitro [9-12]. Many plausible mechanisms would explain this pro-cancer effect: the induction of genetic instability [11, 13, 14], alterations in metabolism [2, 3, 15], and dramatic changes in the expression of many genes. Specific genes include known tumor suppressors and oncogenes [16, 17] and many potent cell signals, such as pro-inflammatory cytokines and other growth factors [15, 18-21]. Infected tumor cells or adjacent infected cells may synthesize cytokines and growth factors that promote the growth of nascent tumor cells. Increased growth rate, along with increased mutation rate, would facilitate the transformation of infected cells.
We were the first to demonstrate that mycoplasma oncogenically transformed human lung cells [12]. We also discovered that mycoplasma species rank among the best known inducers of bone morphogenetic protein (BMP) 2 [12]. This is particularly relevant to lung cancer, because BMP2 RNA and protein levels are abnormally elevated in lung tumors [22-24]. BMP2 activates pro-oncogenic pathways (e.g., PI3K/mTOR; Smad1,5/Id-1) and promotes lung tumor growth in mice [25-27]. The BMP2 antagonist, noggin, reduces mixed metastatic lung cancer lesions in bone [28] and the growth of transformed lung cells in monolayer and in soft agar [12]. Finally, high BMP2 levels are associated with poor patient survival [29].
At the least, mycoplasma infection is a potential biomarker for prostate malignancy. At best, the prostate cancer/mycoplasma link suggests that more aggressive antibiotic treatment of mycoplasma-infected men may be beneficial. Although smoking is the most important cause of lung cancer, other factors contribute to the development of lung cancer [30]. Proof that mycoplasma also influences lung cancer would facilitate the prevention and/or treatment of lung cancer. In addition, understanding the signals such as BMP2 that mediate the effect of mycoplasma may reveal other therapeutic options for a disease that is the leading cause of cancer deaths in the United States.
REFERENCES
- 1.Cimolai N. Do mycoplasmas cause human cancer? Can J Microbiol. 2001;47:691–7. [PubMed] [Google Scholar]
- 2.Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18:757–89. doi: 10.1128/CMR.18.4.757-789.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17:697–728. doi: 10.1128/CMR.17.4.697-728.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and different human carcinomas. World J Gastroenterol. 2001;7:266–9. doi: 10.3748/wjg.v7.i2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pehlivan M, Itirli G, Onay H, Bulut H, Koyuncuoglu M, Pehlivan S. Does Mycoplasma sp. play role in small cell lung cancer? Lung Cancer. 2004;45:129–30. doi: 10.1016/j.lungcan.2004.01.007. [DOI] [PubMed] [Google Scholar]
- 6.Pehlivan M, Pehlivan S, Onay H, Koyuncuoglu M, Kirkali Z. Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma? Urology. 2005;65:411–4. doi: 10.1016/j.urology.2004.10.015. [DOI] [PubMed] [Google Scholar]
- 7.Barykova YA, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, Rakovskaya IV, Baker PS, Shyshynova I, Stephenson AJ, Klein EA, Naroditsky BS, Gintsburg AL, Gudkov AV. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget. 2011 doi: 10.18632/oncotarget.256. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hrbacek J, Urban M, Hamsikova E, Tachezy R, Eis V, Brabec M, Heracek J. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer. 2011;11:53. doi: 10.1186/1471-2407-11-53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009;4:e6872. doi: 10.1371/journal.pone.0006872. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Feng SH, Tsai S, Rodriguez J, Lo SC. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol. 1999;19:7995–8002. doi: 10.1128/mcb.19.12.7995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Tsai S, Wear DJ, Shih JW, Lo SC. Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci U S A. 1995;92:10197–201. doi: 10.1073/pnas.92.22.10197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Jiang S, Zhang S, Langenfeld J, Lo SC, Rogers MB. Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by post-transcriptional mechanisms. J Cell Biochem. 2007;104:580–594. doi: 10.1002/jcb.21647. [DOI] [PubMed] [Google Scholar]
- 13.Fogh J, Fogh H. Chromosome Changes in Pplo-Infected Fl Human Amnion Cells. Proc Soc Exp Biol Med. 1965;119:233–8. doi: 10.3181/00379727-119-30145. [DOI] [PubMed] [Google Scholar]
- 14.Paton GR, Jacobs JP, Perkins FT. Chromosome changes in human diploid-cell cultures infected with Mycoplasma. Nature. 1965;207:43–5. doi: 10.1038/207043a0. [DOI] [PubMed] [Google Scholar]
- 15.Miller CJ, Kassem HS, Pepper SD, Hey Y, Ward TH, Margison GP. Mycoplasma infection significantly alters microarray gene expression profiles. Biotechniques. 2003;35:812–4. doi: 10.2144/03354mt02. [DOI] [PubMed] [Google Scholar]
- 16.Zhang B, Shih JW, Wear DJ, Tsai S, Lo SC. High-level expression of H-ras and c-myc oncogenes in mycoplasma-mediated malignant cell transformation. Proc Soc Exp Biol Med. 1997;214:359–66. doi: 10.3181/00379727-214-44104. [DOI] [PubMed] [Google Scholar]
- 17.Logunov DY, Scheblyakov DV, Zubkova OV, Shmarov MM, Rakovskaya IV, Gurova KV, Tararova ND, Burdelya LG, Naroditsky BS, Ginzburg AL, Gudkov AV. Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene. 2008;27:4521–31. doi: 10.1038/onc.2008.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yang J, Hooper WC, Phillips DJ, Talkington DF. Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae. Infect Immun. 2002;70:3649–55. doi: 10.1128/IAI.70.7.3649-3655.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zhang S, Tsai S, Lo SC. Alteration of gene expression profiles during mycoplasma-induced malignant cell transformation. BMC Cancer. 2006;6:116. doi: 10.1186/1471-2407-6-116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhang S, Wear DJ, Lo S. Mycoplasmal infections alter gene expression in cultured human prostatic and cervical epithelial cells. FEMS Immunol Med Microbiol. 2000;27:43–50. doi: 10.1111/j.1574-695X.2000.tb01410.x. [DOI] [PubMed] [Google Scholar]
- 21.Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev. 2004;15:157–68. doi: 10.1016/j.cytogfr.2004.01.001. [DOI] [PubMed] [Google Scholar]
- 22.Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009;66:319–26. doi: 10.1016/j.lungcan.2009.02.020. [DOI] [PubMed] [Google Scholar]
- 23.Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005;80:1028–32. doi: 10.1016/j.athoracsur.2005.03.094. [DOI] [PubMed] [Google Scholar]
- 24.Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003;24:1445–54. doi: 10.1093/carcin/bgg100. [DOI] [PubMed] [Google Scholar]
- 25.Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res. 2005;3:679–84. doi: 10.1158/1541-7786.MCR-05-0124. [DOI] [PubMed] [Google Scholar]
- 26.Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 2006;25:685–92. doi: 10.1038/sj.onc.1209110. [DOI] [PubMed] [Google Scholar]
- 27.Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2:141–9. [PubMed] [Google Scholar]
- 28.Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, Huard J, Dubinett S, Lieberman JR. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and rank:Fc administration. J Bone Miner Res. 2006;21:1571–80. doi: 10.1359/jbmr.060706. [DOI] [PubMed] [Google Scholar]
- 29.Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–24. doi: 10.1038/nm733. [DOI] [PubMed] [Google Scholar]
- 30.Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327–43. doi: 10.1097/01.JTO.0000263718.69320.4c. [DOI] [PubMed] [Google Scholar]
